Metaplastic carcinoma of the breast with chondroid differentiation (matrix-producing carcinoma): study of the diagnostic cost-effectiveness of fine-needle aspiration biopsy and needle core biopsy. 2014

M T Soler Monsó, and I Català, and M Terricabras, and A Petit, and F Climent, and L Pérez-Casanovas, and A Gumà, and I Morilla
Department of Pathology, Hospital Universitari de Bellvitge/IDIBELL, Barcelona, Spain.

Metaplastic carcinoma with chondroid differentiation (MMPC) is a subtype of breast metaplastic carcinoma with mesenchymal differentiation. Although fine-needle aspiration (FNAB) and core-needle biopsy (CNB) are commonly used for the diagnosis of breast cancer, not enough studies proving the diagnostic cost-effectiveness of these techniques for the identification of MMPC have been published so far. The aim of this study was to investigate the concordance between the presurgical diagnosis using FNAB/CNB and the definitive diagnosis in the surgical specimen in pure MMPC. A case of MMPC is also reported. METHODS All cases of MMPC diagnosed in our institution from 1995 to 2011 were reviewed. The presence of chondroid differentiation in cytological studies or biopsies and the proportion of chondroid matrix in the surgical specimen were evaluated. RESULTS A total of 13 cases of pure MMPC were collected. The diagnosis was suspected in 25% of FNABs and was rendered in 40% of CNBs. CONCLUSIONS The chondroid component in MMPC is hard to identify by FNAB and CNB. The random distribution and proportion of the chondroid differentiation in the tumour and the expertise in performing the technique and in identifying the chondroid component may play an important role in the diagnosis of MMPC using these techniques.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D044963 Biopsy, Fine-Needle Using fine needles (finer than 22-gauge) to remove tissue or fluid specimens from the living body for examination in the pathology laboratory and for disease diagnosis. Aspiration Biopsy, Fine-Needle,Fine Needle Biopsy,Fine-Needle Aspiration,Aspiration Biopsies, Fine-Needle,Aspiration Biopsy, Fine Needle,Aspiration, Fine-Needle,Aspirations, Fine-Needle,Biopsies, Fine Needle,Biopsies, Fine-Needle,Biopsies, Fine-Needle Aspiration,Biopsy, Fine Needle,Biopsy, Fine-Needle Aspiration,Fine Needle Aspiration,Fine Needle Biopsies,Fine-Needle Aspiration Biopsies,Fine-Needle Aspiration Biopsy,Fine-Needle Aspirations,Fine-Needle Biopsies,Fine-Needle Biopsy,Needle Biopsies, Fine,Needle Biopsy, Fine
D062005 Biopsy, Large-Core Needle The use of needles usually larger than 14-gauge to remove tissue samples large enough to retain cellular architecture for pathology examination. Biopsy, Core Needle,Core Needle Biopsy,Large-Core Needle Biopsy,Biopsies, Core Needle,Biopsies, Large-Core Needle,Biopsy, Large Core Needle,Core Needle Biopsies,Large Core Needle Biopsy,Large-Core Needle Biopsies,Needle Biopsies, Core,Needle Biopsies, Large-Core,Needle Biopsy, Core,Needle Biopsy, Large-Core

Related Publications

M T Soler Monsó, and I Català, and M Terricabras, and A Petit, and F Climent, and L Pérez-Casanovas, and A Gumà, and I Morilla
January 1991, Acta cytologica,
M T Soler Monsó, and I Català, and M Terricabras, and A Petit, and F Climent, and L Pérez-Casanovas, and A Gumà, and I Morilla
April 2005, Zhonghua bing li xue za zhi = Chinese journal of pathology,
M T Soler Monsó, and I Català, and M Terricabras, and A Petit, and F Climent, and L Pérez-Casanovas, and A Gumà, and I Morilla
December 2011, Cytopathology : official journal of the British Society for Clinical Cytology,
M T Soler Monsó, and I Català, and M Terricabras, and A Petit, and F Climent, and L Pérez-Casanovas, and A Gumà, and I Morilla
February 2018, The American journal of case reports,
M T Soler Monsó, and I Català, and M Terricabras, and A Petit, and F Climent, and L Pérez-Casanovas, and A Gumà, and I Morilla
May 1998, Cancer,
M T Soler Monsó, and I Català, and M Terricabras, and A Petit, and F Climent, and L Pérez-Casanovas, and A Gumà, and I Morilla
April 2006, Yonsei medical journal,
M T Soler Monsó, and I Català, and M Terricabras, and A Petit, and F Climent, and L Pérez-Casanovas, and A Gumà, and I Morilla
March 2019, Cytopathology : official journal of the British Society for Clinical Cytology,
M T Soler Monsó, and I Català, and M Terricabras, and A Petit, and F Climent, and L Pérez-Casanovas, and A Gumà, and I Morilla
November 2006, Diagnostic cytopathology,
M T Soler Monsó, and I Català, and M Terricabras, and A Petit, and F Climent, and L Pérez-Casanovas, and A Gumà, and I Morilla
May 2007, Journal of clinical pathology,
M T Soler Monsó, and I Català, and M Terricabras, and A Petit, and F Climent, and L Pérez-Casanovas, and A Gumà, and I Morilla
February 2009, Annals of surgical oncology,
Copied contents to your clipboard!